STRATA Skin Sciences, Inc.
SSKN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.68 | -0.19 | -0.49 | 4.75 |
| FCF Yield | -1.31% | -2.88% | -1.70% | -0.43% |
| EV / EBITDA | -42.21 | -59.44 | 245.77 | 286.04 |
| Quality | ||||
| ROIC | -41.64% | -28.26% | -12.00% | -13.07% |
| Gross Margin | 56.85% | 55.34% | 60.20% | 66.22% |
| Cash Conversion Ratio | -0.02 | 0.05 | 0.20 | -0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.46% | 3.63% | 16.13% | -1.73% |
| Free Cash Flow Growth | 73.85% | -18.84% | -117.25% | -3,304.76% |
| Safety | ||||
| Net Debt / EBITDA | -3.23 | -2.62 | 2.67 | -2.64 |
| Interest Coverage | -4.39 | -5.25 | -5.02 | -14.02 |
| Efficiency | ||||
| Inventory Turnover | 6.45 | 5.57 | 2.59 | 2.90 |
| Cash Conversion Cycle | 52.42 | 32.17 | 98.94 | 65.84 |